# KLOW Peptide Research — Component Studies on Wound Healing, Inflammation and Matrix Repair > KLOW peptide research: TB-500 wound re-epithelialization, BPC-157 tendon repair, KPV NF-kappaB inhibition, GHK-Cu transcriptome data. Cited, component-attributed. ## In plain English KLOW peptide research means four separate bodies of literature, not one. Each peptide in the blend has been studied on its own — in cells, in animal models, and in a small number of human trials. None of the four is studied as a combined KLOW blend. This page summarizes what the component studies have found, with each finding labeled to the peptide it belongs to. The wound-reepithelialization data for the TB-500 arm are the strongest single-model results in the KLOW record. The angiogenesis and tendon data for BPC-157 are the most extensive rodent literature. KPV has clear cell-culture evidence for anti-inflammatory signaling. GHK-Cu has both cell-culture and some controlled human topical data. ## TB-500 arm: wound re-epithelialization KLOW research on wound closure begins with thymosin beta-4 (Tbeta4) — the 43-amino-acid native protein whose seven-amino-acid actin-binding fragment is marketed as TB-500. In a rat full-thickness wound model, topical or IP thymosin beta-4 increased re-epithelialization (the regrowth of the surface tissue layer) by 42% at four days and by up to 61% at seven days versus saline controls. Wound contraction was increased by at least 11% by day seven. Collagen deposition and angiogenesis were raised. In scratch-assay (cell migration) experiments, as little as 10 pg stimulated keratinocyte migration two- to three-fold — a remarkably low active concentration [1]. A separate study confirmed concurrent angiogenesis, wound-healing and hair-follicle effects in rodent models, documenting thymosin beta-4 as a multi-endpoint repair signal [12]. In a Phase 1 trial of full-length synthetic thymosin beta-4 in 40 healthy volunteers, IV doses from 42 to 1260 mg (given as a single dose then daily for 14 days) were well tolerated with no dose-limiting toxicities and no serious adverse events; pharmacokinetics were dose-proportional [8]. This is human safety data for the native protein, not for the seven-amino-acid TB-500 fragment. A 2026 Sports Medicine review covering unapproved musculoskeletal peptides including TB-500 / thymosin beta-4 confirms animal-model promise but underlines that human safety data remain scarce, with potential for serious harm, and that these compounds operate largely outside regulatory oversight [7]. **The TB-500 fragment distinction is critical.** Most foundational efficacy data — including the Malinda 1999 wound findings [1] and the Ruff 2010 Phase 1 trial [8] — are for full-length thymosin beta-4, not the short Ac-LKKTET-Q fragment. The fragment carries the G-actin sequestration motif (the mechanism that drives cell migration) but not the integrin-linked kinase activation or epicardial progenitor mobilization established for the native protein. Equating TB-500 with thymosin beta-4 in efficacy claims overstates what the fragment literature supports. ## BPC-157 arm: tendon repair and angiogenesis BPC-157 research spans more than three decades of rodent models. The tendon data are among the most replicated. Fully transected Wistar rat Achilles tendons healed better with IP BPC-157 (10 microg, 10 ng or 10 pg per rat per day) versus untreated controls across biomechanical load-to-failure testing, functional gait assessment, microscopic collagen organization and macroscopic tendon integrity. In vitro tendocyte (tendon-cell) outgrowth was also stimulated at all three doses [2]. The primary mechanism is activation of the VEGFR2 (vascular endothelial growth factor receptor 2) / PI3K / Akt / eNOS angiogenesis pathway — a signaling cascade that promotes formation of new blood vessels in injured tissue. BPC-157 also modulates the nitric-oxide system in a manner that is partly resistant to L-NAME (a standard NOS inhibitor), suggesting an NO route distinct from classical NOS chemistry. Growth-hormone receptor upregulation in tendon fibroblasts is a third reported mechanism. In 2025, the first human IV safety data appeared: intravenous BPC-157 at 10 mg on day one and 20 mg on day two in two healthy adults (a 58-year-old male and a 68-year-old female) was well tolerated with no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [6]. Tiny n; not an efficacy trial. Recent work (2025-2026) extends the tissue contexts. BPC-157 reduced liver, kidney and lung injury secondary to acute pancreatitis in rats [13]. A separate 2026 study documents fistula resolution mediated through the NO system [14]. A 2025 literature and patent review surveys the compound's multifunctional record [15]. ## KLOW research: GHK-Cu arm GHK-Cu (glycyl-histidyl-lysine copper complex) was first isolated from human plasma by Loren Pickart in 1973. Plasma GHK concentration declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a natural aging gradient used to motivate the supplementation rationale [4]. In a 2015 review of clinical and in vitro data, GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid in comparative studies. GHK-Cu stimulates synthesis of collagen (type I and IV), dermatan sulfate, chondroitin sulfate and the proteoglycan decorin. Topical GHK-Cu produced documented placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [4]. A gene-expression analysis using bioinformatic methods found that GHK modulates approximately 31.2% of human protein-coding genes at a 50% or greater expression-change threshold — increasing 59% of those genes and suppressing 41%, with the strongest signals on extracellular-matrix remodeling, ubiquitin-proteasome quality control (41 upregulated genes), DNA repair and antioxidant defense [5]. The widely circulated '~4,000 genes' figure is an extrapolation; the 50%-threshold table covers on the order of 2,100 genes. A controlled human trial of a topical formulation combining 5-aminolevulinic acid and the GHK peptide (not chelated to copper) in 45 men with androgenetic alopecia showed statistically significant hair-count increases versus placebo over six months — an increase of 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05), with no adverse events [11]. GHK-Cu also upregulates SIRT1 (a deacetylase enzyme linked to cellular stress responses), deacetylates STAT3 (a transcription factor in inflammatory signaling) and suppresses the Th17 inflammatory pathway in colitis models [4][5]. ## KPV arm: NF-kappaB inhibition KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone), the 13-residue pituitary hormone. As the terminal three residues of a natural anti-inflammatory signal, KPV inherits part of alpha-MSH's NF-kappaB pathway inhibition in a far smaller, more membrane-permeable molecule. In human intestinal epithelial cell lines (Caco-2 and HT29) and Jurkat T cells in culture, nanomolar KPV (10 nM) reduced NF-kappaB p65 nuclear import, attenuated MAPK ERK/p38 signaling, and reduced secretion of TNF-alpha, IL-6, IL-1beta and IL-8. The mechanism depends on uptake via PepT1 (SLC15A1), the di/tripeptide transporter expressed at high levels in inflamed intestinal epithelium, with a KPV substrate Km of approximately 160 microM [3]. In live mice with DSS-induced colitis and TNBS-induced colitis (two standard models of intestinal inflammation), oral KPV in drinking water (100 microM) reduced colitis severity on histological and inflammatory-marker endpoints [3]. Human data for KPV are limited: the compound's clinical lineage runs through alpha-MSH-based IBD programs rather than as a standalone approved drug. No approved KPV product exists. ## The blend gap No controlled study has tested the four-peptide KLOW blend — against any monotherapy, against any subset, or against placebo. Every claim that the combination outperforms individual components is a mechanistic extrapolation. The pharmacokinetic mismatch (the tripeptides clear faster than BPC-157) means a single vial cannot deliver all four at matched exposures in any single dosing window. The combination rationale is biologically plausible. It is not evidenced. See [KLOW references](/references) for the full citation list. --- A blueprint of the component literature — four peptides drawn against their own studies, the untested blend left as the one honest empty node.